CONMED Corporation
NYSE:CNMD · New York Stock Exchange
+$0.24 today
Vol 0.64M · Avg 0.45M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.6%
avg 4.7%
ROIC
4.6%
avg 4.4%
ROA
2.0%
avg 2.2%
Analysis
ROIC is currently the strongest return metric at 4.6% versus its period average of 4.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Patrick J. Beyer | President, Chief Executive Officer & Director | $2.63M | — | 60 | $28,145.00 | 0.09% |
Curt R. Hartman | Special Advisor | $2.05M | — | 62 | $118,300.00 | 0.39% |
Todd W. Garner | Advisor | $1.30M | — | 57 | $1,836.00 | <0.01% |
Hollie Foust | Executive Vice President, General Counsel and Corporate Secretary | $842,764.00 | — | 51 | $12,940.00 | 0.04% |
Brent Lalomia | Executive VP of Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations & IT | $787,817.00 | — | 51 | $941.06 | <0.01% |
Peter K. Shagory | Executive Vice President of Strategy & Corporate Development | $713,756.00 | — | 57 | $16,926.00 | 0.06% |
John Ferrell | Executive Vice President of Human Resources | — | — | 58 | $16,926.00 | 0.06% |
Kimberly A. Lockwood | Interim Corporate Controller & Interim Principal Accounting Officer | — | — | 49 | $0.00 | <0.01% |
Keith Seaton | Vice President of Compliance | — | — | — | — | — |
Richard Glaze | Chief Information Officer | — | — | 60 | $0.00 | <0.01% |
Josep Lluis Llorens | Executive VP Global Supply Chain Management & Operations | — | — | 63 | — | — |
Andrew Moller | Interim Principal Financial Officer, VP & Corporate Controller | — | — | 51 | $5,896.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$299,505.44
Net Sentiment
$299,505.44
Net selling
Most Active
Garner Todd W
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 5 sells worth $299,505.44 over the last 12 months. That adds up to net selling of $299,505.44. Garner Todd W was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -8.2% | +13.1% (13yr)1 analysts |
| Revenue | N/A | N/A | -2.1% | +5.9% (13yr)4 analysts |
| Net Income | N/A | N/A | -9.0% | +14.1% (13yr)4 analysts |
| EBIT | N/A | N/A | -7.8% | +11.2% (13yr)4 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.1% over three years. Forward estimates point to Net Income at +14.1% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.52B
Neogen Corporation
NASDAQ:NEOG
$1.97B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.83B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.71B
NovoCure Limited
NASDAQ:NVCR
$1.71B
AdaptHealth Corp.
NASDAQ:AHCO
$1.30B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.11B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
InMode Ltd.
NASDAQ:INMD
$814.53M
SS Innovations International, Inc.
NASDAQ:SSII
$674.44M
Who manages CNMD?
CONMED Corporation (CNMD) lists 12 active executives. The top listed executive is Todd W. Garner, Advisor.
Are CNMD insiders buying or selling?
Recent insider activity shows net buying of $44.98M.
Explore More
Continue the stock analysis
Jump to another research area for this company.